1.	Multicenter Selective Lymphadenectomy Trial II (MSLT-II) Phase: Phase III Type: Diagnostic, Treatment Status: Active Age: 18 to 75 Sponsor: NCI, Other Protocol IDs: MSLT-II, NIH P01 CA029605, NCT00297895
2.	Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: 103A-301, NCT01546571
3.	A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GO27826, 2011-004011-24, NCT01667419
4.	Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 07.0008, NCT00553618
5.	177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 78,256, NCT01237457
6.	Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 90 Sponsor: NCI, Other Protocol IDs: VICC MEL 1263, NCI-2012-01699, NCT01701037
7.	Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ALS-357-001, NCT00701987
8.	Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: J1112, NCT01435499
9.	Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma Phase: Phase I Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 10-229, NCT01456104
10.	Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: I 191511, NCI-2011-03568, NCT01522820
11.	A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 15781, NCT01585350
12.	Randomized Study of the Effects of Sargramostim (GM-CSF) Versus Incomplete Freund's Adjuvant (Montanide ISA-51) Versus GM-CSF and Montanide ISA-51 on Dermal Dendritic Cells at or Around the Tumor Site in Patients With Stage I or II Melanoma Phase: No phase specified Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment Status: Active Age: 18 to 85 Sponsor: NCI Protocol IDs: UVACC-MEL-38, UVACC-14499, UVACC-HIC-8380
13.	Pilot Study of IFN a2b for Melanoma Patients Phase: No phase specified Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-067, NCT00871533
14.	Study to Assess the Safety and Immunological Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 15398, NCT01425749
15.	Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: MC0972, NCI-2012-01610, NCT01748747